Abstract
Objective: The impridone ONC201 (Oncoceutics), a dopamine receptor D2 (DRD2) antagonist, has antitumorigenic effects in preclinical studies, including high-grade serous (HGS) ovarian cancer (OC). ONC206, a derivative of ONC201 that shares the imipridone core structure, is a DRD2 antagonist that exhibits distinct receptor pharmacology and nanomolar potency. Thus, we investigated the antitumorigenic potential and potency of ONC206 in serous OC cell lines and mouse models.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
